BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, April 20, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Aug. 15, 2005
View Archived Issues
THP's Transgenic Rabbits To Make Polyclonal Drugs
Read More
BioVeris Licenses Exclusive Vaccine Rights From Baxter
Read More
U.S. Patent Disclosures
Read More
Other News To Note
Read More
Alexion Raises $67M As Lead Drugs Near End Of Phase III
Just days after Alexion Pharmaceuticals Inc. said it completed enrollment in a pivotal trial of its cardiovascular drug, pexelizumab, ahead of schedule, the company priced a public offering to raise $66.9 million. (BioWorld Today)
Read More
$33M Financing, Loans Could Take Xenogen To Profitability
Read More